Becton, Dickinson and Company (BDX) Receives “Buy” Rating from Stifel Nicolaus
Stifel Nicolaus restated their buy rating on shares of Becton, Dickinson and Company (NYSE:BDX) in a research report released on Friday. The brokerage currently has a $245.00 target price on the medical instruments supplier’s stock.
A number of other research analysts have also weighed in on the company. Piper Jaffray Companies reaffirmed a buy rating and set a $213.00 price objective on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Zacks Investment Research lowered Becton, Dickinson and from a hold rating to a sell rating in a report on Monday, October 9th. Wells Fargo & Company began coverage on Becton, Dickinson and in a report on Friday, September 22nd. They issued an outperform rating and a $225.00 target price on the stock. Bank of America Corporation reissued a buy rating and issued a $225.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Finally, BidaskClub raised Becton, Dickinson and from a buy rating to a strong-buy rating in a report on Tuesday, July 11th. Five analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $211.94.
Shares of Becton, Dickinson and (NYSE:BDX) traded up $0.31 during mid-day trading on Friday, reaching $224.41. The company had a trading volume of 1,410,000 shares, compared to its average volume of 1,230,000. Becton, Dickinson and has a 52-week low of $161.29 and a 52-week high of $224.89. The firm has a market capitalization of $51,070.00, a price-to-earnings ratio of 23.61, a PEG ratio of 1.77 and a beta of 1.04. The company has a debt-to-equity ratio of 1.48, a current ratio of 5.56 and a quick ratio of 5.01.
Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The firm had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. During the same quarter in the prior year, the company posted $2.12 earnings per share. Becton, Dickinson and’s quarterly revenue was down 2.0% on a year-over-year basis. equities research analysts anticipate that Becton, Dickinson and will post 10.65 earnings per share for the current year.
In other news, EVP Linda M. Tharby sold 4,695 shares of the company’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $200.48, for a total value of $941,253.60. Following the sale, the executive vice president now directly owns 18,670 shares in the company, valued at $3,742,961.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ellen R. Strahlman sold 9,283 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total value of $1,839,983.43. Following the completion of the sale, the insider now owns 26,638 shares in the company, valued at $5,279,917.98. The disclosure for this sale can be found here. Insiders sold 75,904 shares of company stock worth $15,242,688 over the last 90 days. Company insiders own 1.40% of the company’s stock.
Several large investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA lifted its position in shares of Becton, Dickinson and by 18.6% in the third quarter. BNP Paribas Arbitrage SA now owns 159,716 shares of the medical instruments supplier’s stock valued at $29,911,000 after acquiring an additional 25,088 shares in the last quarter. Suffolk Capital Management LLC purchased a new stake in shares of Becton, Dickinson and in the third quarter valued at $10,116,000. FDx Advisors Inc. lifted its position in Becton, Dickinson and by 2.0% during the third quarter. FDx Advisors Inc. now owns 15,557 shares of the medical instruments supplier’s stock worth $3,048,000 after buying an additional 306 shares during the period. Global X MANAGEMENT CO LLC lifted its position in Becton, Dickinson and by 9.8% during the third quarter. Global X MANAGEMENT CO LLC now owns 4,175 shares of the medical instruments supplier’s stock worth $818,000 after buying an additional 371 shares during the period. Finally, Bessemer Group Inc. lifted its position in Becton, Dickinson and by 0.9% during the third quarter. Bessemer Group Inc. now owns 987,226 shares of the medical instruments supplier’s stock worth $193,447,000 after buying an additional 9,176 shares during the period. Institutional investors and hedge funds own 86.70% of the company’s stock.
About Becton, Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.